Access Challenges in Retinal Vascular DiseasesByJonathan Jonisch, MD,Anton Kolomeyer, MD PhD,David A. Eichenbaum, MD, FASRS,Esther Lee Kim, MDJuly 13th 2026
Managing Retinal Vascular Diseases in Clinical PracticeByJonathan Jonisch, MD,Anton Kolomeyer, MD PhD,David A. Eichenbaum, MD, FASRS,Esther Lee Kim, MDJuly 13th 2026
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial diseaseByOphthalmology Times Staff ReportsJuly 7th 2026
NeuroOp Guru: What a big data study reveals about NAION and stroke riskByAndrew G. Lee, MD,Andrew Carey, MDJuly 7th 2026
Port Delivery System Therapies in Retinal Vascular DiseasesByJonathan Jonisch, MD,Anton Kolomeyer, MD PhD,David A. Eichenbaum, MD, FASRS,Esther Lee Kim, MDJuly 6th 2026